24th May 2022 | Pharma Updates
Macleods Pharma, TBO, and others receive approval for initial public offerings
Macleods Pharmaceuticals, TBO Tek, and Suraj Estate Developers have all received approval from capital markets regulator Sebi to raise funds through initial public offerings (IPOs).
Akums Drugs received approval to manufacture Bempedoic acid tablets in India
Akums Drugs and Pharma has obtained the licence to manufacture and commercialise Bempedoic acid, a class of drug used to treat high LDL-cholesterol conditions that are indicative of cardiovascular disease.
Dapagliflozin from AstraZeneca meets primary endpoint in DELIVER phase III trial
Dapagliflozin from AstraZeneca achieved a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) fatality or worsening heart failure (HF).
Glenmark Pharma receives five observations from the USFDA for its Goa, India facility
USFDA issued Form 483 with five observations following an inspection at Glenmark Pharmaceuticals Limited’s formulation manufacturing facility in Goa, India, between May 12, 2022 and May 20, 2022.
Swiperx receives $27 million from MDI and the Gates Foundation
SwipeRx, a pharma professional platform, announced a $27 million Series B round led by Indonesia’s MDI Ventures, with participation from the Gates Foundation, Johnson & Johnson Impact Ventures, Susquehanna International Group, and existing backers.
Actis acquired Rx Propellant, a company based in Hyderabad
Actis, a global investor, has acquired Rx Propellant, a Hyderabad-based company that provides real estate solutions to tenants in the life sciences and related industries. Rx Propellant is a market leader in life sciences real estate.
Tukysa, a potential breast cancer blockbuster from Seagen shows promise in colorectal cancer
The company announced positive top-line results from the Mountaineer 2 trial, which looked at the use of Tukysa plus chemotherapy (Roche’s Herceptin) in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC).